Results 81 to 90 of about 22,257 (214)

Long non-coding RNA (H19) in patients with spondyloarthritis: association with disease parameters and ultrasonographic findings

Egyptian Rheumatology and Rehabilitation
Background Spondyloarthritis is a well-known chronic inflammatory disorder; despite recent advances, its genetic basis remains poorly understood. Recently, long non-coding RNA (H19) was identified to be associated with various human cancers and studied ...
A. I. EL-Zwawy, Eiman Soliman, Eman T. Elsayed, Mai M. Morsy   +3 more
doaj   +1 more source

Recommendations for the treatment of axial spondyloarthritis: An analysis of the updated ASAS/EULAR 2022 clinical guidelines

Научно-практическая ревматология
The article discusses the 2022 updated version of the collaborative ASAS/EULAR (Assessment in SpondyloArthritis international Society/European Alliance of Associations for Rheumatology) recommendations for the treatment of axial spondyloarthritis.
Sh. F. Erdes, T. V. Dubinina
doaj   +1 more source

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis [PDF]

, 2015
Objective. To evaluate the efficacy and safety of adalimumab in patients with active nonpsoriatic peripheral spondyloarthritis (SpA). Methods. ABILITY-2 is an ongoing phase III, multicenter study of adalimumab treatment.
Karunaratne, P Mahinda, Mease, Philip, Pangan, Aileen L, Rahman, Proton, Sieper, Joachim, Van den Bosch, Filip   +5 more
core   +1 more source

Vitamin D Deficiency in Axial Spondyloarthritis is Associated With Higher Disease Activity [PDF]

, 2017
Objectives: This study aims to assess whether vitamin D deficiency is associated with increased disease activity and functional impairment in axial spondyloarthritis (axSpA), with control for its seasonal variation.Patients and methods: Serum 25 ...
Duffield, Stephen, Goodson, Nicola, Thong, Daniel, Zhao, Sizheng   +3 more
core   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

A NEW CONCEPT OF SPONDYLOARTHRITIS: A COMPROMISE BETWEEN ASAS AND GRAPPA?

Научно-практическая ревматология, 2018
The paper briefly discusses the history of spondyloarthritis (SpA) from the article published by J. Moll et al. in 1974 to the present day. The discussion of the recent SpA concept proposed by the Assessment of SpondyloArthritis International Society ...
Sh. F. Erdes
doaj   +1 more source

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis:Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors [PDF]

, 2019
Objective: To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi).
Antolini, Christopher, Azevedo, Valderilio, Barkham, Magnus, Barragan, Sergio Duran, Berman, Alberto, Blasco, Francisco Navarro, Blicharski, Tomasz, Brzezicki, Jan, Burmester, Gerd, Carlier, Hilde, Carrio, Judith, Cocco, Jose Maldonado, Collantes, Eduardo, Combe, Bernard, Cons‐Molina, Fidencio, Cortes‐Maisonet, Gregorio, Deodhar, Atul, Dudek, Anna, Elkayam, Ori, Fernandez, Carlos Gonzalez, Flint, Kathleen, Gaffney, Karl, Galeazzi, Mauro, Gaylis, Norman, Goddard, David, Goupille, Philippe, Greenwald, Maria, Gremese, Elisa, Hong, Seung Jae, Howell, Mary, Hrycaj, Pawel, Ince, Akgun, Jesus, Amarilis Perez‐De, Ju, Ji Hyeon, Järvinen, Pentti, Kaine, Jeffrey, Kang, Seong Wook, Keiserman, Mauro, Kim, Tae‐Hwan, Kivitz, Alan, Klein, Steven, Kremer, Joel, Krishnan, Eswar, Lee, Chang Keun, Lee, Eun Bong, Lee, Sang Heon, Lee, Sang‐Hoon, Lespessailles, Eric, Li, Xiaoqi, Lidman, Roger, Loveless, James, Lucero, Eleonora, Marcolino, Flora, Mariette, Xavier, Masmitja, Jordi Gratacos, Mehta, Daksha, Morin, Frederic, Moscovici, Yolanda, Mueller, Eric, Mysler, Eduardo, Nguyen, Minh,, Pacheco‐Tena, Cesar, Pantojas, Carlos, Park, Min‐Chan, Peters, Eric, Plebanski, Rafal, Poddubnyy, Denis, Querubin, Roel, Rahman, Proton, Reitblat, Tatiana, Remus, Cesar Ramos, Reveille, John, Rivera, Tania, Rodriguez, Aaron Alejandro Barrera, Rodriguez, Juan Cruz Rizo, Salvarani, Carlo, Sanchez‐Burson, Juan, Sande, Marleen, Santisteban, Silvia, Sayers, Michael, Scotton, Antonio, Scoville, Craig, Shaw, David, Shin, Kichul, Singhal, Atul, Skinner, Cassandra, Soto‐Raices, Oscar, Soubrier, Martin, Szymanska, Malgorzata, Thai, Christine, Wells, Alvin, Wojciechowski, Rafal, Xavier, Ricardo,, Ximenes, Antonio, Zhao, Fangyi, Zisman, Devy   +95 more
core   +6 more sources

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

Autoimmunity and Periodontitis

Journal of Periodontal Research, EarlyView.
In a microbe‐driven inflammatory environment, peptidyl‐arginine deiminase (PAD) enzymes from neutrophils and Porphyromonas gingivalis citrullinate both microbial and self‐antigens. B cell presentation of citrullinated or self‐mimicking epitopes activates T cells that assist B cells in antibody isotype switching, affinity maturation, epitope spreading ...
Massimo Costalonga, Vivek Thumbigere‐Math, Mark C. Herzberg   +2 more
wiley   +1 more source

Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients [PDF]

, 2016
Spondyloarthritis (SpA) and inflammatory bowel disease (IBD) are chronic autoinflammatory diseases that partially share the genetic predisposition and the unchecked inflammatory response linking the gut to the joints.
Ascolani, M, Biancone, L, Calabrese, E, Chimenti, Ms, Conigliaro, P, Lolli, E, Novelli, L, Onali, S, Pallone, F, Perricone, R, Petruzziello, C, Triggianese, P   +11 more
core   +1 more source